KRAS and non-small cell lung carcinoma: In clinical studies, patients with Stage I non-small cell lung cancer (NSCLC) or liver metastasis treated with ablative radiation (i.e. stereotactic body radiation therapy, SBRT) whose tumors were KRAS mutant had worse local control compared to patients with KRAS wild-type tumors [29, 30].